Review · United States
Liraglutide
Reviewed on
Approval and product status
FDA-approved products exist for specific indications
The ingredient name alone does not tell you which approved product the evidence covers. Liraglutide is an active ingredient. Victoza and Saxenda are distinct approved products with different labeled indications and product-specific prescribing information.
What was measured in people?
- Health results · Strong
- Large randomized programs support defined glycemic, cardiovascular, and weight-management outcomes.
- Body changes · Strong
- Approved labels characterize product-specific exposure, pharmacodynamics, and interactions.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
The current label has important reasons a product may not be appropriate, plus warnings and precautions. This guide does not determine eligibility or provide dose, titration, or product-switching instructions.
Still unknown: These results do not show the same benefit for every person. They do not establish an anti-aging effect or show that approved products are equivalent to compounded, counterfeit, or research-labeled material.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
Victoza
- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Type 2 diabetes uses and labeled populations defined in the current product prescribing information.
Published label: November 2024
Read the published Victoza FDA label (PDF)Saxenda
- Ingredients and form
- Injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Chronic weight management in the adult and pediatric populations defined in the current label.
Published label: February 2026
Read the published Saxenda FDA label (PDF)What the research shows
Studies and FDA-reviewed labels support specific outcomes. LEADER studied heart and blood-vessel outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.
Read all Liraglutide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 4 sources
- VICTOZA (liraglutide) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- SAXENDA (liraglutide) prescribing information
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- Liraglutide and cardiovascular outcomes in type 2 diabetes
PubMed · New England Journal of Medicine · Randomized trial · 2016
Source accessed
- Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed